USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...

Australians with a high risk of developing lung cancer can be screened for the disease free of charge through Medicare.This is ...

Understanding how tumors manipulate their microenvironment is key to improving cancer immunotherapy. A recent study has revealed that PKM2, a metabolic enzyme released from necrotic tumor cells, acts ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

FirstHealth of the Carolinas will offer free lung cancer screenings using its mobile Lung Bus at FirstHealth Lee Campus located at 2919 Beechtree Drive in Sanford from 8:30 a.m. to 12:30 p.m. on ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...